Gilead Sciences' (NASDAQ:GILD) experimental antiviral drug remdesivir appears to have been unsuccessful in treating COVID-19 in a late-stage study conducted by the Chinese government. The World Health Organization (WHO) inadvertently posted a summary of results from the study on its website on Thursday before quickly removing the information. That summary stated that "remdesivir was not associated with clinical or virological benefits." 

Premature conclusions?

The report on the Chinese clinical study was only a draft document -- it's still being reviewed by scientists before WHO officially releases the findings.

Gloved hand holding a tiny globe with a pushpin in China

Image source: Getty Images.

Even if the full context of the final results of the study confirms that remdesivir didn't provide clinical benefits to COVID-19 patients, there will still be plenty of questions. The Chinese study was ended early because of low enrollment. Without enough patients in the study, the data won't be statistically meaningful.

In addition, that apparent negative result contrasts with recent updates from two other remdesivir studies. Earlier this month, The New England Journal of Medicine published initial results from an analysis of COVID-19 patients being treated with remdesivir under a compassionate-use program. Those results pointed to encouraging signs of efficacy for the drug. Also, healthcare industry news website STAT reported last week that early data from a late-stage clinical study of remdesivir being conducted at the University of Chicago showed very promising results. 

Next up

Gilead expects to release preliminary data from a late-stage study of the drug in treating patients with severe cases of COVID-19 by the end of April. Initial data from a National Institutes for Health study and Gilead's study focusing on patients with moderate symptoms of COVID-19 will be announced in May.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.